Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing engineered virotherapies and related cell-based delivery platforms for cancer treatment. The company is advancing product candidates such as CLD-101 and CLD-201, while also building the manufacturing, regulatory, and intellectual property infrastructure needed to support future clinical and commercial development. It currently has no product sales and remains dependent on external financing to fund research, development, and operations. Calidi is headquartered in the United States and also operates through subsidiaries in Germany and Australia to support parts of its development and trial activities.
1.59
1.59
| % | |
|---|---|
| Oncolytic virotherapy programs | 70% Engineered virus-based cancer therapeutics designed to attack tumors and stimulate anti-tumor immune responses. |
| Cell-based delivery platforms | 20% Cell therapy approaches used to deliver therapeutic payloads and improve targeting of tumor sites. |
| Preclinical and clinical development | 10% Research, toxicology, trial execution, and regulatory work required to advance product candidates. |
Calidi does not currently sell commercial products, so its near-term 'customers' are primarily research partners,...
Hospitals, investigators, and trial vendors that support the testing of CLD-101 and CLD-201 in patients.
Specialty manufacturers and suppliers that produce clinical-grade viral and cell therapy materials for development programs.
Universities and research institutions that license foundational IP and may receive contingent payments if programs advance.
Biopharma companies that could license, co-develop, or commercialize Calidi’s candidates after clinical validation.
Calidi is based in the United States, where its principal executive and administrative offices and laboratory facility...
Calidi’s strategy is centered on advancing its current and future product candidates through preclinical and clinical...
The company has stated it does not have sufficient cash to support operations for at least one year and needs funding to continue development.
Clinical progress is required to create value, support regulatory filings, and eventually enable commercialization.
Third-party partnerships could provide non-dilutive funding and commercialization capabilities that Calidi does not yet have.
Calidi faces substantial going-concern and financing risk because it has no product revenue and expects continuing...
Management disclosed that current cash is not sufficient to support operations for at least one year and that substantial additional funding is required.
The company’s value depends on advancing unapproved product candidates through preclinical and clinical stages, where failure rates are high.
Without product revenue, the company must fund operations through equity offerings, debt, or partnerships, which may not be available on favorable terms.
Clinical drug product and supply are sourced from vendors, making timelines and costs vulnerable to third-party performance.
Operations in Germany and Australia and use of European vendors create exposure to exchange-rate and cross-border execution issues.
PLUR · Biological Products, (No Diagnostic Substances)
TVRD · Pharmaceutical Preparations
Tvardi Therapeutics is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapies for fibrosis-driven diseases and certain cancers.
CALC · Pharmaceutical Preparations
IMUX · Pharmaceutical Preparations
CLYM · Pharmaceutical Preparations
MGX · Biological Products, (No Diagnostic Substances)
: 28.4.2026